Skip to main content
Premium Trial:

Request an Annual Quote

Shamrock Structures to Provide Structural Proteomics Services for Trubion Pharmaceuticals

NEW YORK, Nov. 19 (GenomeWeb News) -  Shamrock Structures will provide integrated structural proteomics services for Trubion Pharmaceuticals, the company said today.


Shamrock, based in Woodridge, Ill., will perform crystallization, collect synchrotron data, and determine the structure of proteins developed by Trubion in return for an upfront fee and performance-based milestone payments.


Trubion Pharmaceuticals, based in Seattle, is focused on the discovery and development of drugs to treat inflammatory diseases and cancer.


Additional terms were undisclosed.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.